Prestige requests Type 4 meeting with FDA in relation to Tuznue® (biosimilar trastuzumab)

Oct 13, 2022

Prestige Biopharma announced that it has submitted a request to the FDA for a pre-submission meeting to discuss the planned BLA for Tuznue® (biosimilar trastuzumab).  Prestige announced that it plans to submit the BLA by the end of the year.

Print Page Mail Article